Related Experiment Video
Updated: Jun 29, 2025
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
Cognitive phenotype and neurodegeneration associated with Tau in Huntington's disease
Saul Martinez-Horta1,2,3,4,5, Jesús Perez-Perez1,2,3,4,5, Rocío Perez-Gonzalez3,6
1Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Insights
Tau pathology is linked to severe cognitive decline and brain damage in Huntington's disease (HD). Higher levels of total Tau (tTau) and phosphorylated Tau (pTau) correlate with worse cognitive symptoms and posterior brain atrophy in HD patients.
Area of Science:
- Neuroscience
- Neurology
- Biochemistry
Background:
- Huntington's disease (HD) exhibits significant clinical heterogeneity, particularly in cognitive decline and associated brain changes, even among individuals with similar disease burden.
- Understanding the underlying mechanisms of this heterogeneity is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the association between Tau pathology and more severe cognitive phenotypes and brain damage in early-to-middle stage Huntington's disease.
- To explore the role of Tau biomarkers in explaining cognitive and neurodegenerative heterogeneity in HD.
Main Methods:
- A cohort of 30 early-to-middle stage HD participants underwent comprehensive neuropsychological testing.
- Structural magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) analysis were performed to quantify Tau biomarkers (tTau, pTau-231) and neurofilament light chain (NfL).
- Relationships between biomarker levels, cognitive performance, and brain integrity were analyzed.
Main Results:
- Severe cognitive deterioration in HD extends beyond executive dysfunction to posterior-cortical dependent processes.
- Higher CSF levels of tTau and pTau-231 were associated with this more severe cognitive phenotype.
- This cognitive profile correlated with pronounced posterior-cortical atrophy in brain regions implicated in Tau-related cognitive deficits.
Conclusions:
- Findings support a strong link between Tau pathology, cognitive impairment, and neurodegeneration in Huntington's disease.
- Tau pathology plays a significant role in the observed cognitive heterogeneity within HD.
- Further research into Tau's role is warranted to address HD's complex clinical variability.
Objective:
The clinical phenotype of Huntington's disease (HD) can be very heterogeneous between patients, even when they share equivalent CAG repeat length, age, or disease burden. This heterogeneity is especially evident in terms of the cognitive profile and related brain changes. To shed light on the mechanisms participating in this heterogeneity, the present study delves into the association between Tau pathology and more severe cognitive phenotypes and brain damage in HD.
Methods:
We used a comprehensive neuropsychological examination to characterize the cognitive phenotype of a sample of 30 participants with early-to-middle HD for which we also obtained 3 T structural magnetic resonance image (MRI) and cerebrospinal fluid (CSF). We quantified CSF levels of neurofilament light chain (NfL), total Tau (tTau), and phosphorylated Tau-231 (pTau-231). Thanks to the cognitive characterization carried out, we subsequently explored the relationship between different levels of biomarkers, the cognitive phenotype, and brain integrity.
Results:
The results confirmed that more severe forms of cognitive deterioration in HD extend beyond executive dysfunction and affect processes with clear posterior-cortical dependence. This phenotype was in turn associated with higher CSF levels of tTau and pTau-231 and to a more pronounced pattern of posterior-cortical atrophy in specific brain regions closely linked to the cognitive processes affected by Tau.
Interpretation:
Our findings reinforce the association between Tau pathology, cognition, and neurodegeneration in HD, emphasizing the need to explore the role of Tau in the cognitive heterogeneity of the disease.
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:37Neural Regulation
01:11Genetic Lingo